Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Chabanon

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Genome Medicine|November 4, 2025
Genome instability and crosstalk with the immune responseRoman M Chabanon, François-Xavier Danlos, Kaissa Ouali, et al.
Molecular & Cellular Oncology|May 28, 2019
Beyond DNA repair: the novel immunological potential of PARP inhibitorsRoman M Chabanon, Jean-Charles Soria, Christopher J Lord, et al.
Computer Methods in Biomechanics and Biomedical Engineering|September 27, 2012
Discrete model combined with mimetic microfluidic chips to study cell growth in porous scaffold under flow conditionsM Chabanon, H Duval, O Francais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2016
Mutational Landscape and Sensitivity to Immune Checkpoint BlockersRoman M Chabanon, Marion Pedrero, Céline Lefebvre, et al.
Nature Reviews. Cancer|August 11, 2021
Targeting the DNA damage response in immuno-oncology: developments and opportunitiesRoman M Chabanon, Mathieu Rouanne, Christopher J Lord, et al.
The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
The Journal of Clinical Investigation|February 16, 2018
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockadeMehdi Touat, Tony Sourisseau, Nicolas Dorvault, et al.
Nature Communications|July 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancersRoman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki, et al.
Cancer Research|April 23, 2021
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in CancerRoman M Chabanon, Daphné Morel, Thomas Eychenne, et al.
Genome Research|April 14, 2018
Enduring epigenetic landmarks define the cancer microenvironmentRuth Pidsley, Mitchell G Lawrence, Elena Zotenko, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Genome Medicine|November 4, 2025
Genome instability and crosstalk with the immune responseRoman M Chabanon, François-Xavier Danlos, Kaissa Ouali, et al.
Molecular & Cellular Oncology|May 28, 2019
Beyond DNA repair: the novel immunological potential of PARP inhibitorsRoman M Chabanon, Jean-Charles Soria, Christopher J Lord, et al.
Computer Methods in Biomechanics and Biomedical Engineering|September 27, 2012
Discrete model combined with mimetic microfluidic chips to study cell growth in porous scaffold under flow conditionsM Chabanon, H Duval, O Francais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2016
Mutational Landscape and Sensitivity to Immune Checkpoint BlockersRoman M Chabanon, Marion Pedrero, Céline Lefebvre, et al.
Nature Reviews. Cancer|August 11, 2021
Targeting the DNA damage response in immuno-oncology: developments and opportunitiesRoman M Chabanon, Mathieu Rouanne, Christopher J Lord, et al.
The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
The Journal of Clinical Investigation|February 16, 2018
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockadeMehdi Touat, Tony Sourisseau, Nicolas Dorvault, et al.
Nature Communications|July 29, 2025
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancersRoman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki, et al.
Cancer Research|April 23, 2021
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in CancerRoman M Chabanon, Daphné Morel, Thomas Eychenne, et al.
Genome Research|April 14, 2018
Enduring epigenetic landmarks define the cancer microenvironmentRuth Pidsley, Mitchell G Lawrence, Elena Zotenko, et al.
Pageof 3